CAB-ROR2-ADC Safety and Efficacy Study in Patients With TNBC or Head & Neck Cancer (Ph1) and NSCLC or Melanoma (Ph2)

Inclusion Criteria:

• Patients must have histologically or cytologically confirmed locally advancedunresectable or metastatic solid tumor and have failed all available standard ofcare (SoC) therapy and for whom no curative therapy is available or who are noteligible, intolerant to or refuse standard therapy.

• Patients must have measurable disease.

• For the dose expansion phase: Patients with locally advanced unresectable ormetastatic, non-small cell lung cancer (NSCLC), triple negative breast cancer (TNBC)and soft tissue sarcoma (STS)

• Age ≥ 18 years.

• Adequate renal function

• Adequate liver function

• Adequate hematological function

• Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.

• Life expectancy of at least three months.

Exclusion Criteria:

• Patients must not have clinically significant cardiac disease.

• Patients must not have known non-controlled CNS metastasis.

• Patients must not have a history of ≥ Grade 3 allergic reactions to mAb therapy aswellas known or suspected allergy or intolerance to any agent given during thisstudy.

• Patients must not have had major surgery within 4 weeks before first BA3021administration.

• Patients must not have had prior therapy with a conjugated or unconjugatedauristatin derivative/vinca-binding site targeting payload.

• Patients must not have known human immunodeficiency virus (HIV) infection, activehepatitis B and/or hepatitis C.

• Patients must not be women who are pregnant or breast feeding.